360 related articles for article (PubMed ID: 35915021)
1. Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis.
Murchison S; Nichol A; Speers C; Gondara L; Levasseur N; Lohrisch C; Vallieres I; Truong P
Clin Breast Cancer; 2022 Oct; 22(7):e773-e787. PubMed ID: 35915021
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy of Taxanes With or Without Anthracyclines in Different Molecular Subtypes of Breast Cancer: A Propensity Score Matching Study.
Xiao J; Wang T; Yi J; Huang M; Yan C; Ling R
Clin Breast Cancer; 2023 Dec; 23(8):882-893. PubMed ID: 37833133
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
4. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
6. Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy.
Kim D; Kim JH; Kim IA; Chang JH; Shin KH
Cancer Res Treat; 2023 Apr; 55(2):592-602. PubMed ID: 36228653
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
Gülben K; Berberoğlu U; Kinaş V; Başkan E
Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
10. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
12. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK
Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
15. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
Yamazaki N; Wada N; Yamauchi C; Yoneyama K
Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
[TBL] [Abstract][Full Text] [Related]
16. pN0(i+) and pN1mi Breast Cancer: Treatment and Outcomes in Comparison With pN0 and pN1a in the Modern Era.
Dosani M; Hamilton SN; Gondara L; Speers C; Diocee RM; Nichol A; Lohrisch C; Truong P
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):805-815. PubMed ID: 35385784
[TBL] [Abstract][Full Text] [Related]
17. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
19. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
20. Locoregional therapy in breast cancer patients treated with neoadjuvant chemotherapy.
Murchison S; Truong P
Expert Rev Anticancer Ther; 2021 Aug; 21(8):865-875. PubMed ID: 33719866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
